Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line therapy in ovarian cancer trials.
Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Thigpen T, et al. Among authors: gallardo d. Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d. Int J Gynecol Cancer. 2011. PMID: 21543937 Review.
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, Aguirre G, Oñate-Ocaña LF, Gallardo D, Otero J. Fuentes H, et al. Among authors: gallardo d. Anticancer Drugs. 2006 Jun;17(5):565-70. doi: 10.1097/00001813-200606000-00011. Anticancer Drugs. 2006. PMID: 16702814 Clinical Trial.
The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer.
Santibáñez M, Gallardo D, Morales F, López A, Prada D, Mendoza J, Castro C, de León DC, Oñate LF, Perez D, Mohar A, Herrera LA. Santibáñez M, et al. Among authors: gallardo d. Pharmacogenet Genomics. 2013 Apr;23(4):190-9. doi: 10.1097/FPC.0b013e32835ea08a. Pharmacogenet Genomics. 2013. PMID: 23407047
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN. Villarreal-Garza C, et al. Among authors: gallardo ln, gallardo d. Cancer. 2015 Feb 1;121(3):372-8. doi: 10.1002/cncr.29058. Epub 2014 Sep 18. Cancer. 2015. PMID: 25236687 Free PMC article.
193 results